These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Shotgun proteomics using the iTRAQ isobaric tags. Aggarwal K; Choe LH; Lee KH Brief Funct Genomic Proteomic; 2006 Jun; 5(2):112-20. PubMed ID: 16772272 [TBL] [Abstract][Full Text] [Related]
23. Structural optimization of an aptamer generated from Ligand-Guided Selection (LIGS) resulted in high affinity variant toward mIgM expressed on Burkitt's lymphoma cell lines. Zümrüt HE; Batool S; Van N; George S; Bhandari S; Mallikaratchy P Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1825-1832. PubMed ID: 28363693 [TBL] [Abstract][Full Text] [Related]
24. Stability of the Human Plasma Proteome to Pre-analytical Variability as Assessed by an Aptamer-Based Approach. Daniels JR; Cao Z; Maisha M; Schnackenberg LK; Sun J; Pence L; Schmitt TC; Kamlage B; Rogstad S; Beger RD; Yu LR J Proteome Res; 2019 Oct; 18(10):3661-3670. PubMed ID: 31442052 [TBL] [Abstract][Full Text] [Related]
25. Profiling of the plasma proteome across different stages of human heart failure. Egerstedt A; Berntsson J; Smith ML; Gidlöf O; Nilsson R; Benson M; Wells QS; Celik S; Lejonberg C; Farrell L; Sinha S; Shen D; Lundgren J; Rådegran G; Ngo D; Engström G; Yang Q; Wang TJ; Gerszten RE; Smith JG Nat Commun; 2019 Dec; 10(1):5830. PubMed ID: 31862877 [TBL] [Abstract][Full Text] [Related]
26. Antibody-Based Proteomics. Wingren C Adv Exp Med Biol; 2016; 926():163-179. PubMed ID: 27686812 [TBL] [Abstract][Full Text] [Related]
27. [Advances in high-throughput proteomic analysis]. Wu Q; Sui X; Tian R Se Pu; 2021 Feb; 39(2):112-117. PubMed ID: 34227342 [TBL] [Abstract][Full Text] [Related]
28. Aptamers and the next generation of diagnostic reagents. Thiviyanathan V; Gorenstein DG Proteomics Clin Appl; 2012 Dec; 6(11-12):563-73. PubMed ID: 23090891 [TBL] [Abstract][Full Text] [Related]
29. Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells. Billing AM; Ben Hamidane H; Bhagwat AM; Cotton RJ; Dib SS; Kumar P; Hayat S; Goswami N; Suhre K; Rafii A; Graumann J J Proteomics; 2017 Jan; 150():86-97. PubMed ID: 27613379 [TBL] [Abstract][Full Text] [Related]
30. The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. Ostroff R; Foreman T; Keeney TR; Stratford S; Walker JJ; Zichi D J Proteomics; 2010 Jan; 73(3):649-66. PubMed ID: 19755178 [TBL] [Abstract][Full Text] [Related]
31. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis. Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786 [TBL] [Abstract][Full Text] [Related]
32. Proteome-Derived Peptide Libraries for Deep Specificity Profiling of N-terminal Modification Reagents. Bridge HN; Weeks AM Curr Protoc; 2023 Jun; 3(6):e798. PubMed ID: 37283519 [TBL] [Abstract][Full Text] [Related]
33. Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platforms. Haslam DE; Li J; Dillon ST; Gu X; Cao Y; Zeleznik OA; Sasamoto N; Zhang X; Eliassen AH; Liang L; Stampfer MJ; Mora S; Chen ZZ; Terry KL; Gerszten RE; Hu FB; Chan AT; Libermann TA; Bhupathiraju SN Proteomics; 2022 Jul; 22(13-14):e2100170. PubMed ID: 35598103 [TBL] [Abstract][Full Text] [Related]
34. Proteomics for heart failure risk stratification: a systematic review. Kuku KO; Oyetoro R; Hashemian M; Livinski AA; Shearer JJ; Joo J; Psaty BM; Levy D; Ganz P; Roger VL BMC Med; 2024 Jan; 22(1):34. PubMed ID: 38273315 [TBL] [Abstract][Full Text] [Related]
35. Systematic antibody and antigen-based proteomic profiling with microarrays. Ayoglu B; Häggmark A; Neiman M; Igel U; Uhlén M; Schwenk JM; Nilsson P Expert Rev Mol Diagn; 2011 Mar; 11(2):219-34. PubMed ID: 21405972 [TBL] [Abstract][Full Text] [Related]
36. Immunocapture strategies in translational proteomics. Fredolini C; Byström S; Pin E; Edfors F; Tamburro D; Iglesias MJ; Häggmark A; Hong MG; Uhlen M; Nilsson P; Schwenk JM Expert Rev Proteomics; 2016; 13(1):83-98. PubMed ID: 26558424 [TBL] [Abstract][Full Text] [Related]
37. Protocol: MYTHBUSTERS: a universal procedure for sample preparation for mass spectrometry. Drabik A; Ner-Kluza J; Bodzon-Kulakowska A; Suder P Eur J Mass Spectrom (Chichester); 2016; 22(5):269-273. PubMed ID: 27882893 [TBL] [Abstract][Full Text] [Related]
38. Using feature selection and Bayesian network identify cancer subtypes based on proteomic data. Wang Y; Gao X; Ru X; Sun P; Wang J J Proteomics; 2023 May; 280():104895. PubMed ID: 37024076 [TBL] [Abstract][Full Text] [Related]
39. Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling. Petrera A; von Toerne C; Behler J; Huth C; Thorand B; Hilgendorff A; Hauck SM J Proteome Res; 2021 Jan; 20(1):751-762. PubMed ID: 33253581 [TBL] [Abstract][Full Text] [Related]
40. Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Nilsson P; Paavilainen L; Larsson K; Odling J; Sundberg M; Andersson AC; Kampf C; Persson A; Al-Khalili Szigyarto C; Ottosson J; Björling E; Hober S; Wernérus H; Wester K; Pontén F; Uhlen M Proteomics; 2005 Nov; 5(17):4327-37. PubMed ID: 16237735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]